Efficacy and Safety of Omalizumab for the Treatment of Severe or Poorly Controlled Allergic Diseases in Children: A Systematic Review and Meta-Analysis

Overview of attention for article published in Frontiers in Pediatrics, March 2022

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (68th percentile)
High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

policy: 1 policy source

twitter: 2 X users

Citations

dimensions_citation: 8 Dimensions

Readers on

mendeley: 27 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Biologic Drugs for Severe Asthma

Cited by Canadian Agency for Drugs and Technologies in Health on 30 Apr 2024

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.